| __timestamp | Alnylam Pharmaceuticals, Inc. | MorphoSys AG |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 9689000 |
| Thursday, January 1, 2015 | 60610000 | 10431000 |
| Friday, January 1, 2016 | 89354000 | 9618000 |
| Sunday, January 1, 2017 | 199365000 | 12348000 |
| Monday, January 1, 2018 | 382359000 | 28310241 |
| Tuesday, January 1, 2019 | 479005000 | 59336147 |
| Wednesday, January 1, 2020 | 588420000 | 159145941 |
| Friday, January 1, 2021 | 620639000 | 199800000 |
| Saturday, January 1, 2022 | 770658000 | 90225000 |
| Sunday, January 1, 2023 | 795646000 | 92538000 |
| Monday, January 1, 2024 | 975526000 |
Data in motion
In the competitive world of biotechnology, effective cost management is crucial. Alnylam Pharmaceuticals, Inc. and MorphoSys AG, two prominent players, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive expansion and investment in operational capabilities. In contrast, MorphoSys AG's expenses grew by approximately 850%, indicating a more conservative approach.
These trends underscore the diverse strategies employed by biotech firms in managing operational costs, offering valuable insights for investors and industry analysts.
Breaking Down SG&A Expenses: AbbVie Inc. vs MorphoSys AG
Breaking Down SG&A Expenses: Merck & Co., Inc. vs MorphoSys AG
Regeneron Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG Trends and Insights
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Alnylam Pharmaceuticals, Inc. or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Merus N.V.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? Walgreens Boots Alliance, Inc. or MorphoSys AG
Cost Management Insights: SG&A Expenses for ADMA Biologics, Inc. and MorphoSys AG